BGPartner | Attorneys-at-law’s Post

#lawsuitoftheweek: Zantac Cancer Lawsuit ⚖️ Court Ruling: A Delaware judge has ruled that GSK, Pfizer, and other pharmaceutical companies must face state court trials over claims that their former heartburn drug Zantac causes cancer. This decision impacts approximately 75,000 lawsuits, allowing expert witnesses to testify on the alleged cancer risk. 🔬 Upcoming Trials: Zantac jury trials are scheduled in Chicago for June, July, September, and November of 2024, and in Philadelphia starting in February 2025. This extensive schedule reflects the significant number of cases awaiting resolution. 💼 Settlements: Pfizer has agreed to settle more than 10,000 Zantac lawsuits, surpassing Sanofi’s recent settlement of 4,000 lawsuits. These settlements indicate the companies’ desire to resolve the litigation despite ongoing trials. Stay tuned as we continue to monitor developments in the Zantac litigation. #legalnews #mdl #legalupdates #masstorts #zantac

Thoughts on this? >> J&J increases talc settlement by $1.1B after negotiating with plaintiffs, lawyers say >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

New Case Study 📣 Learn how we used our business development process to successfully secure a licensing partnership for an oncology asset (while retaining U.S. rights) within 6 months. #licensing #pharma #biopharma #partnering #strategicpartner #druglicensing #pharmalicensing Get the case study: https://buff.ly/3JUupfI

This week, MWP Partners became substantial holders of Island Pharmaceuticals, alongside some biotech heavies (with significantly more scientific pedigree than our own) including Daniel Tillett, Jason Carroll, Bill Garner and Chris Ntoumenopoulos. The capital provided will ensure Island can fully fund its Phase 2a/b trial targeting Dengue Fever and fast track the acquisition of Galidesivir, which primarily targets Ebola. What attracted us to this opportunity: - Large (and growing) market opportunity with Dengue infecting an estimate 400m people annually and no current treatment. - Dengue is becoming a ‘rich country’ problem with global warming expanding carrying mosquitos beyond equatorial regions into Southern America, Southern Europe and Northern Australia. - ILA-101 is a small molecule with clinical history. Having previously been developed by J&J for oncology, it has high safety profile and is well tolerated based on 45 human studies. Animal and cell studies, which for antivirals has great translation into humans, further show ILA-101 prevents viral replication and deaths from lethal Dengue. - The US Army, who are a natural stockpiler of an approved drug, is providing no-dilutive funding and cooperating with its R&D library to provide diluted strains of the virus for Island’s Phase 2 trial. - Dengue is the tip of the iceberg, with many other mosquito-borne disease targets including Zika, West Nile and Yellow Fever. - Island could be eligibile to receive Priority Review Voucher(s) following FDA approval for both ILA-101 and Galidesivir, which can be sold to big pharma for >US$100m a piece, providing substantial dilution-free funding. - Galidesivir has a potentially rapid pathway to market under the FDA’s ‘Animal Rule’, requiring only animal trials given the obvious unethical and safety concerns putting Ebola into humans. The market is beginning to recognise Island's potential and is off to a strong start as we await first readout of the Phase 2a results in November. Follow the journey and hope we put a dent in these crippling viruses. https://lnkd.in/g7-9hDDB

Thoughts on this? >> J&J increases talc settlement by $1.1B after negotiating with plaintiffs, lawyers say >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #productmarketing #pharmaceutical #pharma

EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal. VISCHER advised EraCal on all legal issues related to the transaction. The VISCHER team included Christian Wyss (pictured) (Partner, Corporate/M&A), Pauline Pfirter (Senior Associate, Corporate/M&A) and Lukas Wendt (Associate, Corporate/M&A). Read the article >> https://lnkd.in/dJmpSh79 #Legalcommunitych #legaladvisor #licensing

Cytokinetics' recent $575M deal with Royalty Pharma, featuring $100M upfront and revised royalties, marks a strategic shift from potential M&A towards independent commercialization. The deal restructures royalty terms for aficamten, with royalties set at 4.5% up to $5B in annual sales, and includes significant investments in omecamtiv mecarbil and CK-586. Additionally, the deal offers up to $450M in milestone payments contingent on the commercial success of these drugs and includes a $50M equity stake in Cytokinetics. The move disappointed investors, causing a 17% stock drop to $48.62. Investors had hoped for an M&A deal following positive phase 3 results for aficamten, with rumors of Novartis circling last fall. However, the deal's terms and substantial financial commitments have shifted focus towards long-term independent growth, leading to investor frustration. As the biotech landscape evolves, do you think such deals will set a new precedent for independent market growth amidst complex financial arrangements?

Are you a manufacturer of Digital Therapeutics (DTx) with a focus on the UK market? In this blog post, we delve into the intricacies of Digital Therapeutics (DTx) regulation in the UK, especially in light of Brexit in January 2020. 👉 https://lnkd.in/e98Z_q6u #DTx #DigitalTherapeutics #RegulatoryAffairs #Brexit

The power of an Automated Analyst was apparent yesterday when the FDA delayed its approval for a leukemia drug from Syndax Pharmaceuticals (NASDAQ: SNDX) – resulting in a dip in share price. In short, Syndax reported that the FDA decision on the drug was pushed back three months from the original September date. But what did this mean for Syndax stock? Not only can Charli alert us to events and news that impact stock portfolios, it can automatically analyze the most recent data to give us an up to date picture. And it is a nice comprehensive report delivered right to our desk; complete with news, analyst commentary, market sentiment, and big-picture financials. This level of analysis cuts through the noise and enables sound long term investment decisions based on facts. #AI #AIFinance #AIInsights #Banking #Syndax #FDA #AIReporting https://hubs.li/Q02JppCB0

This Wednesday, May 22nd, at 12PM EST / 5PM GMT we are hosting an amazing panel with Brenda medina from Kyowa Kirin, Inc.- U.S., Rob Aitchison from 4C, Scott Sawicki, formerly of ADC Therapeutics and Kara Titus of Dragonfly Therapeutics, Inc.. We will discuss clinical vendor management key questions, such as: - why does it cost so much to onboard and qualify clinical vendors? - what can we do, as an industry, to lower the cost of clinical outsourcing? - how to we become more proactive in managing vendor portfolio risk? Come hear the experts weigh in the questions and ask yours. To register, use the link: